Definium Therapeutics, Inc.
NASDAQ:DFTX · NASDAQ Global Select
-$0.41 today
Vol 1.68M · Avg 2.67M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-55.3%
avg -57.9%
ROIC
-44.5%
avg -47.7%
ROA
-41.8%
avg -45.4%
Analysis
ROA is currently the strongest return metric at -41.8% versus its period average of -45.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Robert Barrow | Chief Executive Officer & Director | $1.05M | — | 37 | $752,454.00 | 0.69% |
Daniel Rollings Karlin | Chief Medical Officer | $738,733.00 | — | 46 | $413,317.00 | 0.38% |
Mark R. Sullivan | Chief Legal Officer & Corporate Secretary | $638,607.00 | — | 55 | $271,079.00 | 0.25% |
Brandi L. Roberts | Chief Financial Officer | $619,239.00 | — | 52 | $150,000.00 | 0.14% |
Scott Freeman | Co-Founder & Clinical Advisor | $307,918.00 | — | 69 | — | — |
Peter Mack | Senior Vice President of Pharmaceutical Development & Operations | — | — | — | — | — |
Beth Calitri | Vice President of Corporate Communications | — | — | — | — | — |
Gitanjali Jain | VP & Head of Investor Relations | — | — | — | — | — |
Stephanie Fagan | Chief Corporate Affairs Officer | — | — | — | — | — |
Matthew Wiley | Chief Commercial Officer | — | — | 53 | $115,000.00 | 0.11% |
Leonard Latchman | Co-Founder | — | — | — | — | — |
Gregg Pratt | Chief Regulatory & Quality Assurance Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$2.11M
Net Sentiment
$2.11M
Net selling
Most Active
Karlin Daniel
4 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $2.11M over the last 12 months. That adds up to net selling of $2.11M. Karlin Daniel was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.61B
AnaptysBio, Inc.
NASDAQ:ANAB
$2.40B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.91B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.60B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.49B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.46B
Savara Inc.
NASDAQ:SVRA
$1.11B
Xencor, Inc.
NASDAQ:XNCR
$937.92M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$605.61M
Rezolute, Inc.
NASDAQ:RZLT
$481.46M
Who manages DFTX?
Definium Therapeutics, Inc. (DFTX) lists 12 active executives. The top listed executive is Peter Mack, Senior Vice President of Pharmaceutical Development & Operations.
Are DFTX insiders buying or selling?
Recent insider activity shows net buying of $12.30M.
Explore More
Continue the stock analysis
Jump to another research area for this company.